Eli Lilly is considering testing its blockbuster weight-loss drugs in people who are not overweight but are at risk of weight ...

Minnesota led the way on insulin affordability, culminating in 2020 with Tim Walz's signing of a law to cut costs.

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Corp. with ...

Eli Lilly explores expanding its weight-loss drugs, Mounjaro and Zepbound, to individuals with a BMI below 27 to prevent ...

By integrating ultra-rapid acting insulin such as Lyumjev, which responds faster than traditional insulin, Tandem Diabetes ...

In a groundbreaking move, Eli Lilly LLY is set to test its weight-loss medications on individuals who are not overweight but are at risk of gaining weight.

From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...

Six 2025 Lilly Endowment Community Scholar finalists have been selected by the Steuben County Community Foundation, it was ...

The longshoreman’s strike shutting down ports along the East and Gulf Coasts may cause a significant shortage of widely used ...

Stocks had a tough start to October and the fourth quarter, posting losses on Tuesday. Here's what CNBC is watching going ...

The great Simone Biles recently took a quick break from her Gold Over America Tour (GOAT Tour) to play the role of a ...

Aurobindo Pharma receives USFDA approval for Cephalexin tablets, expected to launch in Q3FY25 with CGT designation.